资料显示，苏州泽璟生物制药股份有限公司位于江苏省昆山市玉山镇晨丰路262号，成立日期2009年3月 18日，上市日期2020年1月23日，公司主营业务涉及化学新药及生物新药的研发、生产及销售。主营业 务收入构成为：药品99.97%，医药中间体及原辅料0.02%，资产租赁0.00%。 9月15日，泽璟制药盘中上涨2.12%，截至09:44，报114.89元/股，成交5408.06万元，换手率0.18%，总 市值304.12亿元。 资金流向方面，主力资金净流入208.34万元，特大单买入367.58万元，占比6.80%，卖出0.00元，占比 0.00%；大单买入638.20万元，占比11.80%，卖出797.44万元，占比14.75%。 泽璟制药今年以来股价涨84.38%，近5个交易日跌2.50%，近20日涨3.50%，近60日涨1.08%。 机构持仓方面，截止2025年6月30日，泽璟制药十大流通股东中，中欧医疗健康混合A（003095）位居 第五大流通股东，持股816.63万股，相比上期增加268.75万股。广发医疗保健股票A（004851）位居第 六大流通股东，持股527.45万股，相比上期减少117.14 ...

Core Insights - The company Zejing Pharmaceutical announced that it will present clinical research data for its self-developed drugs Alveltamig (code: ZG006) and Nilvanstomig (code: ZG005) at the 28th Annual Academic Conference of the Chinese Society of Clinical Oncology (CSCO) scheduled for September 10-14, 2025 [2] - The announcement indicates that the release of the latest clinical data will not have a significant impact on the company's recent performance [2] - The pharmaceutical industry is characterized by high technology, high risk, and high added value, with long and complex development cycles for drugs, making them susceptible to various uncertainties [2] Company Developments - The company will fulfill its information disclosure obligations based on subsequent developments related to the clinical trials [2] - The timeline for drug development from research, clinical trials, approval, to production is lengthy and involves multiple stages [2]

证券代码：688266 证券简称：泽璟制药 公告编号：2025-036 苏州泽璟生物制药股份有限公司 关于自愿披露 ZG006 和 ZG005 在第 28 届中国临床肿 瘤学会（CSCO）学术年会发布临床数据及 最新进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、苏州泽璟生物制药股份有限公司（以下简称"公司"）自主研发的新药 Alveltamig（代号：ZG006）、Nilvanstomig（代号：ZG005）的临床研究数据及 最新进展将于2025年9月10日至14日召开的第28届中国临床肿瘤学会（CSCO） 学术年会上发布。 2、本次在 2025 年中国临床肿瘤学会（CSCO）学术年会发布最新临床数据 事项对公司近期业绩不会产生重大影响。由于医药产品具有高科技、高风险、高 附加值的特点，药品前期研发以及产品从研制、临床试验、报批到投产的周期长、 环节多，容易受到一些不确定性因素的影响，公司将及时根据后续进展履行信息 披露义务。敬请广大投资者谨慎决策，注意防范投资风险。 为使各位投资者及时了 ...

Core Insights - The company Zai Lab (stock code: 688266.SH) announced that clinical research data and updates for its self-developed drugs Alveltamig (code: ZG006) and Nilvanstomig (code: ZG005) will be presented at the 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) from September 10 to 14, 2025 [1] Group 1: ZG006 Clinical Research - ZG006 is undergoing a Phase II dose-optimization clinical study (ZG006-002) for the treatment of refractory advanced small cell lung cancer (SCLC) patients, which has been selected for an oral presentation at the conference [1] - As of May 12, 2025, a total of 60 SCLC patients who have undergone three or more lines of treatment were randomly assigned to receive either ZG006 at 10mg Q2W or 30mg Q2W, with the initial dose being 1mg [1] - The baseline characteristics of both patient groups were generally balanced [1] Group 2: ZG005 Clinical Research - ZG005 is being evaluated in a Phase I/II clinical study (ZG005-004) for its safety, pharmacokinetics, and preliminary efficacy in combination with Etoposide and Cisplatin (EP) for first-line treatment of advanced neuroendocrine carcinoma [1] - As of August 21, 2025, a total of 84 patients have been enrolled in the study, with 92.9% of patients having a Ki-67 proliferation index of ≥55% and 64.3% of patients exhibiting liver metastasis [1] - The most common primary tumor site among patients was the gastrointestinal tract, accounting for 36.9% [1]

泽璟制药(688266.SH)发布公告，公司自主研发的新药Alveltamig(代号：ZG006)、Nilvanstomig(代号： ZG005)的临床研究数据及最新进展将于2025年9月10日至14日召开的第28届中国临床肿瘤学会(CSCO)学 术年会上发布。 ZG006单药治疗在难治性晚期小细胞肺癌患者中的II期剂量优化临床研究(ZG006-002)入选本次年会肺癌 专场口头报告。截至2025年5月12日，共60例三线及以上小细胞肺癌(SCLC)患者按1:1随机接受 ZG00610mgQ2W或30mgQ2W治疗并纳入分析。首次给药均为1mg滴定剂量。两组患者的基线特征总体 均衡。 ZG005联合依托泊苷及顺铂(EP)在一线晚期神经内分泌癌患者中的安全性、药代动力学特征及初步疗效 的I/II期临床研究(ZG005-004)数据及最新进展：截至2025年8月21日，共纳入84例患者。92.9%患者Ki- 67增殖指数≥55%，64.3%的患者存在肝转移。最常见的原发肿瘤部位为胃肠道，占36.9%。 ...

Core Viewpoint - The company announced that clinical research data and latest progress for its self-developed drugs Alveltamig (ZG006) and Nilvanstomig (ZG005) will be presented at the CSCO Annual Meeting from September 10 to 14, 2025 [1] Group 1: ZG006 Clinical Data - ZG006 has shown promising results in a Phase II dose-optimization clinical study for patients with refractory advanced small cell lung cancer, with a total of 60 patients included in the analysis as of May 12, 2025 [1] - The best overall response rates (ORR) for the 10 mg Q2W and 30 mg Q2W groups were 60.0% and 63.3% respectively, with confirmed response rates of 53.3% for both groups [1] - Disease control rates (DCR) were reported at 73.3% for the 10 mg Q2W group and 70.0% for the 30 mg Q2W group [1] Group 2: ZG005 Clinical Data - ZG005, in combination with Etoposide and Cisplatin, has been evaluated in a Phase I/II clinical study for first-line treatment of advanced neuroendocrine carcinoma, with 84 patients enrolled as of August 21, 2025 [1] - Among the 60 patients who could be assessed for efficacy, the ORR was reported at 43.8%, 63%, and 29.4% [1]

Core Viewpoint - Zai Lab's stock price has shown significant growth this year, with a notable increase in trading activity and a mixed financial performance in the first half of 2025 [1][2]. Group 1: Stock Performance - On September 9, Zai Lab's stock price decreased by 2.09%, trading at 115.38 CNY per share with a total transaction volume of 350 million CNY and a market capitalization of 30.542 billion CNY [1]. - Year-to-date, Zai Lab's stock has risen by 85.17%, with a 7.63% increase over the last five trading days, 6.06% over the last twenty days, and 0.55% over the last sixty days [1]. Group 2: Financial Performance - For the first half of 2025, Zai Lab reported a revenue of 376 million CNY, representing a year-on-year growth of 56.07%, while the net profit attributable to shareholders was -72.8035 million CNY, a decrease of 9.42% compared to the previous period [2]. Group 3: Shareholder Information - As of June 30, 2025, Zai Lab had 8,795 shareholders, an increase of 16.75% from the previous period, with an average of 30,097 circulating shares per shareholder, down 14.35% [2]. - Notable institutional shareholders include China Europe Medical Health Mixed A and others, with changes in their holdings reflecting varying investment strategies [2].

9月8日，泽璟制药跌5.11%，截至发稿，报114.66元/股，成交4.81亿元，换手率1.57%，总市值303.51亿 元。 资料显示，苏州泽璟生物制药股份有限公司位于江苏省昆山市玉山镇晨丰路262号，成立日期2009年3月 18日，上市日期2020年1月23日，公司主营业务涉及化学新药及生物新药的研发、生产及销售。主营业 务收入构成为：药品99.97%，医药中间体及原辅料0.02%，资产租赁0.00%。 从基金十大重仓股角度 华泰保兴科荣A（009124）基金经理为周咏梅、陈祺伟。 截至发稿，周咏梅累计任职时间7年217天，现任基金资产总规模88.97亿元，任职期间最佳基金回报 43.67%， 任职期间最差基金回报-1.86%。 陈祺伟累计任职时间2年83天，现任基金资产总规模245.94亿元，任职期间最佳基金回报18.51%， 任职 期间最差基金回报-1.86%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，华泰保兴基金旗下1只基金 ...

Core Viewpoint - The biopharmaceutical sector in China is experiencing a positive trend in innovation and investment, with significant growth in the approval of innovative drugs and a recovery in market conditions [1][2] Industry Summary - As of September 8, 2025, the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) increased by 0.89%, with notable gains from companies such as United Imaging Healthcare (688271) up 11.48% and BGI Genomics (688114) up 9.35% [1] - The "National Drug Safety Publicity Week" launched on September 1 highlights the positive development of the pharmaceutical industry, with 210 innovative drugs approved in the past five years, indicating a sustained growth trend [1] - Currently, approximately 30% of the world's innovative drugs under research are from China, showcasing the country's significant role in global pharmaceutical innovation [1] Company Summary - The top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index as of August 29, 2025, include United Imaging Healthcare (688271), BeiGene (688235), and others, collectively accounting for 50.27% of the index [2] - The Sci-Tech Biopharmaceutical ETF (588250) closely tracks the performance of the Sci-Tech Innovation Board Biopharmaceutical Index, reflecting the overall performance of representative biopharmaceutical companies listed on the Sci-Tech Board [2]

Group 1 - The stock price of Zai Jian Pharmaceutical (688266) closed at 120.84 yuan on September 5, 2025, an increase of 18.46% from the previous week's 102.01 yuan [1] - The company's market capitalization is currently 31.987 billion yuan, ranking 18th out of 150 in the chemical pharmaceutical sector and 553rd out of 5152 in the A-share market [1] Group 2 - Zai Jian Pharmaceutical reported a revenue of 376 million yuan for the first half of 2025, representing a year-on-year growth of 56.07%, primarily driven by increased drug sales [2][3] - The company recorded a net loss of 72.8035 million yuan in the same period, with losses slightly widening compared to the previous year [2][3] - Research and development expenses amounted to 197 million yuan, accounting for 52.31% of total revenue [2][3]